RenovoRx Inc. has released a corporate overview highlighting the initial commercialization of its FDA-cleared RenovoCath® device in 2025, with first half revenues exceeding expectations. The company reports that 13 cancer centers have been approved to purchase RenovoCath, with four centers currently using the device with patients as of August 14, 2025. Discussions are ongoing with over 20 additional potential customers. RenovoRx estimates a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with the possibility for expanded applications and a total addressable market in the billions of dollars. The device is protected by patents until 2038 and is part of RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. The company is led by a team with expertise in clinical development and commercial execution in the pharma and medical device sectors. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/A48C6FE2189AC2D45C309FD23D340855EBF64206)